What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will take an oral dose three times a day (with or without food) for up to 24 cycles (a cycle is defined as 28 days).”In the company’s words, NCT06541847 on ClinicalTrials.gov
- Tested for
- Neurofibromatosis Type 1
- Main trialPhase 2
- “The trial will be an open label, single arm, phase 2 study to assess the tolerability and efficacy of HLX-1502 in participants with NF1 that are 16 years or older in age with progressive and/or symptomatic PN. This study will also investigate the safety and efficacy of HLX-1502 in a small cohort of 12 to 15 year olds.”In the company’s words, NCT06541847 on ClinicalTrials.gov
Other drugs for Neurofibromatosis Type 1
- SelumetinibAstraZeneca · Phase 3
- LuvometinibShanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Phase 3
- MirdametinibSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · Phase 2
- TunlametinibShanghai Kechow Pharma, Inc. · Phase 2
- PAS-004Pasithea Therapeutics Corp. · Phase 1
- DabrafenibNovartis · Marketed (Phase 4 trial)
Coming up1
- Jun 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Jun 2027 | A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026